Although a number of studies have attempted to develop inhibitors of NF-κB and its signaling transducers, and many chemotherapeutic agents often function in part by blocking NF-κB signaling, inhibition of this versatile transcription factor and its signaling nonetheless remain an attractive and desirable attribute for development of novel anti-cancer strategies [40]. The gene discussed is NFKB1; the disease is cancer.